Novonesis A/S/€NSISB
1D1W1MYTD1Y5YMAX
Capital at risk
About Novonesis A/S
Novonesis A/S is a biotechnology company formed in January 2024 through the merger of Novozymes and Chr. Hansen. Headquartered in Lyngby, Denmark, the company specializes in developing biosolutions, including enzymes, functional proteins, and microorganisms, serving over 30 industries such as food and beverage, agriculture, and pharmaceuticals. With a global presence encompassing more than 23 manufacturing sites and nearly 40 R&D and application centers, Novonesis employs approximately 10,000 individuals worldwide. The company is committed to sustainability, aiming for carbon neutrality by 2050 and a 75% reduction in scope 1 and 2 emissions by 2030. Novonesis leverages its extensive expertise to create innovative biosolutions that address global challenges in health, nutrition, and environmental sustainability.
- Ticker
- €NSISB
- Sector
- Materials
- Primary listing
- XGAT
- Employees
- 11,098
- Headquarters
- Lyngby, Denmark
- Website
- www.novonesis.com
Novonesis A/S Metrics
BasicAdvanced
€27B
42.37
€1.35
0.62
€0.88
1.54%
Price and volume
Market cap
€27B
Beta
0.62
52-week high
€62.18
52-week low
€45.15
Average daily volume
563K
Dividend rate
€0.88
Financial strength
Current ratio
1.738
Quick ratio
1.036
Long term debt to equity
0.254
Total debt to equity
0.275
Dividend payout ratio (TTM)
64.19%
Interest coverage (TTM)
13.94%
Profitability
EBITDA (TTM)
1,609.5
Gross margin (TTM)
56.39%
Net profit margin (TTM)
14.70%
Operating margin (TTM)
23.30%
Effective tax rate (TTM)
21.32%
Revenue per employee (TTM)
€390,000
Management effectiveness
Return on assets (TTM)
3.79%
Return on equity (TTM)
5.77%
Valuation
Price to earnings (TTM)
42.366
Price to revenue (TTM)
6.227
Price to book
17.95
Price to tangible book (TTM)
5,655.15
Price to free cash flow (TTM)
34.81
Free cash flow yield (TTM)
2.87%
Free cash flow per share (TTM)
1.648
Dividend yield (TTM)
1.54%
Growth
Revenue change (TTM)
4.86%
Earnings per share change (TTM)
-32.02%
3-year revenue growth (CAGR)
21.74%
10-year revenue growth (CAGR)
8.65%
3-year earnings per share growth (CAGR)
-6.42%
10-year earnings per share growth (CAGR)
0.58%
3-year dividend per share growth (CAGR)
3.17%
10-year dividend per share growth (CAGR)
6.57%
Upcoming events
No upcoming events
Funds containing Novonesis A/S
AllEURGBPUSD
Fund name | Fund size | €NSISB weighting |
|---|---|---|
Vanguard FTSE Developed Europe ex UK€VERX | €3.4B | 0.20% |
Vanguard FTSE Developed Europe ex UK£VERX | £2.9B | 0.20% |
Vanguard FTSE Developed Europe€VWCG | €3.1B | 0.15% |
Vanguard FTSE Developed Europe€VEUR | €4.8B | 0.15% |
Vanguard FTSE Developed Europe£VEUR | £4.1B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.